Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34998
Title: Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.
Austin Authors: Perucca, Emilio;French, Jacqueline A;Aljandeel, Ghaieb;Balestrini, Simona;Braga, Patricia;Burneo, Jorge G;Felli, Augustina Charway;Cross, J Helen;Galanopoulou, Aristea S;Jain, Satish;Jiang, Yuwu;Kälviäinen, Reetta;Lim, Shih Hui;Meador, Kimford J;Mogal, Zarine;Nabbout, Rima;Sofia, Francesca;Somerville, Ernest;Sperling, Michael R;Triki, Chahnez;Trinka, Eugen;Walker, Matthew C;Wiebe, Samuel;Wilmshurst, Jo M;Wirrell, Elaine;Yacubian, Elza Márcia;Kapur, Jaideep
Affiliation: Medicine (University of Melbourne)
NYU Grossman School of Medicine and NYU Langone Health, New York, New York, USA.
Faculty of Epileptology, Iraqi Council for Medical Specializations, Medical City, Baghdad, Iraq.
Neuroscience Department, Meyer Children's Hospital, Florence, Italy.;University of Florence, Florence, Italy.;Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Institute of Neurology, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.;Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.;Neuroepidemiology Unit, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
37 Military Hospital, Accra, Ghana.
Developmental Neurosciences Research and Teaching Department, UCL NIHR BRC Great Ormond Street Institute of Child Health, London, UK.;Department of Neurology, Great Ormond Street Hospital, London, UK.;Young Epilepsy, Lingfield, UK.
Isabelle Rapin Division of Child Neurology, Saul R. Korey Department of Neurology, Dominick P Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, New York, USA.
Indian Epilepsy Centre, New Delhi, India.
Department of Pediatrics and Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.;Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.;Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing, China.;Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, Beijing, China.;Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing, China.
Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland.;Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
National Neuroscience Institute, Singapore, Singapore.;Duke-National University of Singapore Medical School, Singapore, Singapore.
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
National Epilepsy Center, Jinnah Postgraduate Medical Center, Karachi, Pakistan.
Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker-Enfants Malades Hospital, Paris, France.;Assistance Publique - Hôpitaux de Paris, member of the European Reference Network EpiCARE, Paris, France.;Institut Imagine - INSERM UMR 1163, Paris, France.;Université Paris Cité, Paris, France.
International Bureau for Epilepsy, Dublin, Ireland.
Prince of Wales Hospital, University of New South Wales, Sydney, New South Wales, Australia.
Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Child Neurology Department, Hedi Chaker University Hospital, LR19ES15, Sfax Medical School, University of Sfax, Sfax, Tunisia.
Department of Neurology, Neurocritical Care, and Neurorehabilitation, Centre for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria.;Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Department of Pediatric Neurology, Red Cross War Memorial Children's Hospital, Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil.
Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.;UVA Brain Institute, University of Virginia, Charlottesville, Virginia, USA.
Issue Date: 27-Jan-2024
Date: 2024
Publication information: Epilepsia 2024-01-27
Abstract: A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English-language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease-modifying" effects. A more-refined terminology to describe precisely these actions needs to be developed.
URI: https://ahro.austin.org.au/austinjspui/handle/1/34998
DOI: 10.1111/epi.17877
ORCID: 0000-0001-8703-223X
0000-0003-2242-8027
0000-0001-5684-0269
0000-0001-5639-1969
0000-0001-7928-375X
0000-0002-3644-2826
0000-0001-6618-2044
0000-0001-7345-4829
0000-0002-0472-2903
0000-0002-0085-6402
0000-0002-5179-9807
0000-0003-2935-5131
0000-0003-1420-0970
0000-0002-7471-882X
0000-0002-4685-2183
0000-0001-5877-4074
0000-0002-3172-2669
0000-0001-8789-1122
0000-0003-0708-6006
0000-0003-2918-3819
0000-0002-5950-2692
0000-0002-0812-0352
0000-0002-1061-9099
0000-0001-7328-1796
0000-0003-3015-8282
0000-0001-8367-0189
0000-0002-8608-1352
Journal: Epilepsia
PubMed URL: 38279786
ISSN: 1528-1167
Type: Journal Article
Subjects: antiepileptic drugs
antiseizure medications
recommendations
terminology
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Oct 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.